— Know what they know.
Not Investment Advice

ELVN NASDAQ

Enliven Therapeutics, Inc.
1W: -1.9% 1M: -4.9% 3M: +62.4% YTD: +171.9% 1Y: +143.1% 3Y: +113.2% 5Y: +31.2%
$41.54
-0.71 (-1.68%)
 
Weekly Expected Move ±6.0%
$36 $39 $41 $44 $46
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 45 · $2.5B mcap · 35M float · 3.08% daily turnover · Short 61% of daily vol

Balance Sheet Trends

Total Assets
$476M +46.2% ▲
5Y CAGR: +39.3%
Total Liabilities
$17M +4.8% ▲
5Y CAGR: +21.1%
Shareholders Equity
$460M +48.3% ▲
5Y CAGR: +40.3%
Cash & Investments
$463M +47.6% ▲
5Y CAGR: +39.3%
Total Debt
$399K +0.0% ▲
Net Debt
-$98M +20.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$110M$76M$100M$124M$99M
Short-Term Investments$0$0$153M$189M$364M
Cash & ST Investments$110M$76M$253M$313M$463M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$2M$10M$5M$12M
Total Current Assets$111M$78M$266M$318M$475M
Property, Plant & Equip.$954K$2M$1M$458K$417K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$54K$0$0$0
Other Non-Current Assets$2M$4M$5M$7M$873K
Total Non-Current Assets$3M$6M$6M$8M$1M
Total Assets$113M$83M$272M$326M$476M
— Liabilities —
Accounts Payable$3M$3M$532K$1M$2M
Short-Term Debt$0$0$0$0$399K
Deferred Revenue$0$6M$0$0$0
Other Current Liabilities$233K$320K$10M$204K$14M
Total Current Liabilities$6M$10M$26M$16M$17M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$714K$150M$67K$0$0
Total Non-Current Liabilities$714K$150M$67K$0$108K
Total Liabilities$6M$160M$26M$16M$17M
— Equity —
Common Stock$1K$1K$41K$49K$59K
Retained Earnings-$45M-$83M-$154M-$243M-$347M
Accumulated OCI$0-$150K$141K$55K$334K
Total Stockholders Equity$107M-$77M$246M$310M$460M
Total Liabilities & Equity$113M$83M$272M$326M$476M
— Key Metrics —
Total Debt$159K$323K$335K$0$399K
Net Debt-$110M-$75M-$100M-$124M-$98M
Total Investments$0$54K$153M$189M$364M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms